The European Neoantigen Summit is the leading meeting dedicated to enhancing the specificity and personalised nature of cancer vaccines and cell-based immunotherapies through the use of individualised, immunogenic neoantigens.

The 2nd Annual European Neoantigen Summit which took place in April 2018 was focused on supercharging tumour targeting through the identification, prediction, and utilisation of the most cutting-edge neoantigen strategies. Join the leaders across pharma and biotech to discuss how the current in silico methods for identifying neoantigens will spur on the next generation of personalised cancer immunotherapies.